Table 3. Correlation between combined CD133/ALDH1 marker expressions and clinicopathological parameters.
| Parameter | Combined CD133/ALDH1 | ||||
|---|---|---|---|---|---|
| Group 1 No. (%) | Group 2 No. (%) | Group 3 No. (%) | Group 4 No. (%) | p-value | |
| Age (yr)* | 0.618 | ||||
| ≤ 35 | 11 (68.8) | 3 (18.8) | 1 (6.6) | 1 (6.3) | |
| > 35 | 163 (59.3) | 42 (15.3) | 52 (18.9) | 18 (6.6) | |
| Tumor size (cm) | <0.001 | ||||
| ≤ 2.0 | 94 (71.2) | 18 (13.6) | 19 (14.4) | 1 (0.8) | |
| > 2.0 | 80 (50.3) | 27 (17.0) | 34 (21.4) | 18 (11.3) | |
| LN metastasis | 0.069 | ||||
| Negative | 120 (64.2) | 29 (15.5) | 30 (16.0) | 8 (4.3) | |
| Positive | 54 (51.9) | 16 (15.4) | 23 (22.1) | 11 (10.6) | |
| Stage | <0.001 | ||||
| I | 77 (71.3) | 15 (13.9) | 15 (13.9) | 1 (0.9) | |
| II | 77 (57.9) | 21 (15.8) | 26 (19.6) | 9 (6.8) | |
| III | 20 (40.0) | 9 (18.0) | 12 (24.0) | 9 (18.0) | |
| Histological grade | 0.085 | ||||
| 1 and 2 | 97 (65.1) | 21 (14.1) | 26 (17.5) | 5 (3.4) | |
| 3 | 77 (54.2) | 24 (17.0) | 27 (19.0) | 14 (9.9) | |
| ER | 0.001 | ||||
| Negative | 33 (31.73) | 21 (20.2) | 33 (31.7) | 17 (16.4) | |
| Positive | 140 (75.3) | 24 (12.9) | 20 (10.8) | 2 (1.1) | |
| PR | 0.157 | ||||
| Negative | 86 (55.1) | 23 (14.7) | 34 (21.8) | 13 (8.3) | |
| Positive | 87 (64.9) | 22 (16.4) | 19 (14.2) | 6 (4.5) | |
| HER2 | <0.001 | ||||
| Negative | 152 (63.1) | 38 (15.8) | 41 (17.0) | 10 (4.2) | |
| Positive | 21 (42.9) | 7 (14.3) | 12 (24.5) | 9 (18.4) | |
| Luminal | <0.001 | ||||
| No | 28 (35.0) | 15 (18.8) | 24 (30.0) | 13 (16.3) | |
| Yes | 145 (69.1) | 30 (14.3) | 29 (13.8) | 6 (2.9) | |
| TNBC | <0.001 | ||||
| No | 151 (65.9) | 32 (14.0) | 34 (14.9) | 12 (5.2) | |
| Yes | 22 (36.1) | 13 (21.3) | 19 (31.2) | 7 (11.5) | |
| RTx | 0.119 | ||||
| No | 61 (62.9) | 9 (9.3) | 17 (17.5) | 10 (10.3) | |
| Yes | 109 (58.9) | 32 (17.3) | 35 (18.9) | 9 (4.9) | |
| CTx* | 0.169 | ||||
| No | 11 (91.7) | 1 (8.3) | 0 | 0 | |
| Yes | 160 (58.8) | 40 (14.7) | 53 (19.5) | 19 (7.0) | |
| Recurrence | 0.003 | ||||
| No | 162 (63.0) | 39 (15.2) | 43 (16.7) | 13 (5.1) | |
| Yes | 12 (35.3) | 6 (17.7) | 10 (29.4) | 6 (17.7) | |
ALDH1=aldehyde dehydrogenase 1; LN=lymph node; ER=estrogen receptor; PR=progesterone receptor; HER2=human epidermal growth factor receptor 2; TNBC=triple-negative breast cancer; RTx=radiotherapy; CTx=chemotherapy; Group 1=CD133-/ALDH1-; Group 2=CD133-/ALDH1+; Group 3=CD133+/ALDH1-; Group 4=CD133+/ALDH1+.
*Fisher exact test.